Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Lenvatinib in HCC with PVTT After Resection
NCT06089382Phase 3Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06089382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089382.